{
    "clinical_study": {
        "@rank": "87459", 
        "acronym": "START2", 
        "arm_group": [
            {
                "arm_group_label": "Tecemotide", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in\n      subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have\n      demonstrated either stable disease or objective response following primary concurrent\n      chemo-radiotherapy (CRT), comparing overall survival (OS) time in subjects treated with\n      tecemotide versus subjects treated with tecemotide-matching placebo."
        }, 
        "brief_title": "Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent, before any trial-related activities are carried out\n\n          -  Histologically or cytologically documented unresectable stage III NSCLC, including\n             bronchioalveolar  carcinomas. Cancer stage must be confirmed and documented by\n             computed tomography (CT), magnetic resonance imaging (MRI) or positron emission\n             tomography (PET) scan\n\n          -  Prior concurrent CRT which is defined as follows:\n\n               -  Minimum of 2 cycles of platinum-based chemotherapy\n\n               -  Radiotherapy with a total tumor dose greater than equal to (>=) 60 Gray and a\n                  single fraction dose >= 1.8 Gray\n\n               -  Overlap of radiotherapy with minimum 2 cycles of platinum-based chemotherapy\n                  (one cycle is defined as either 3 or 4 weeks depending on the chemotherapy\n                  regimen). A deviation of 2 to 3 days from an exact overlap is acceptable. Purely\n                  radiosensitizing doses of chemotherapy are not acceptable (for example [e.g.],\n                  daily low dose regimens; weekly carbo-platinum + paclitaxel regimens are\n                  allowed).\n\n        Subjects must have completed the primary thoracic CRT at least 4 weeks (28 days) and no\n        later than 12 weeks (84 days) prior to randomization. Subjects who received prophylactic\n        brain irradiation as part of primary CRT are eligible.\n\n          -  Documented stable disease or objective response, according to Response Evaluation\n             Criteria in Solid Tumors (RECIST) 1.1, after primary concurrent CRT for unresectable\n             stage III disease, within 4 weeks (28 days) prior to randomization\n\n          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\n          -  A platelet count, white blood cells (WBC) and hemoglobin value as defined in the\n             protocol\n\n          -  Male or female, greater than or equal to 18 years of age\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Undergone lung cancer specific therapy (including surgery) other than initial\n             concurrent CRT\n\n          -  Received chemotherapy during radiotherapy in radiosensitizing doses only (e.g., daily\n             low dose regimens; weekly carbo-platinum + paclitaxel regimens are allowed).\n\n          -  Metastatic disease\n\n          -  Malignant pleural effusion at initial diagnosis, during initial CRT, and/or at trial\n             entry\n\n          -  Past or current history of neoplasm other than lung carcinoma, except for curatively\n             treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer\n             curatively treated and with no evidence of disease for at least 5 years\n\n          -  A recognized immunodeficiency disease including cellular immunodeficiencies,\n             hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary,\n             congenital or acquired immunodeficiencies\n\n          -  Splenectomy\n\n          -  Any preexisting medical condition requiring chronic systemic steroid or\n             immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are\n             allowed)\n\n          -  Receipt of immunotherapy (as defined in the protocol) within 4 weeks prior to\n             randomization\n\n          -  Receipt of investigational systemic drugs (including off-label use of approved\n             products) within 4 weeks prior to randomization\n\n          -  Autoimmune disease\n\n          -  Known active or chronic infectious hepatitis\n\n          -  Infectious process that, in the opinion of the Investigator, could compromise the\n             subject's ability to mount an immune response\n\n          -  Clinically significant hepatic dysfunction, renal dysfunction and cardiac disease as\n             defined in the protocol\n\n          -  Pregnant or breast-feeding women\n\n          -  Known drug abuse/alcohol abuse\n\n          -  Participation in another interventional clinical trial within the past 28 days\n             (excluding purely observational studies)\n\n          -  Requires concurrent treatment with a non-permitted drug\n\n          -  Known hypersensitivity to any of the trial treatment ingredients\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Any other reason that, in the opinion of the Investigator, precludes the subject from\n             participating in the trial\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1002", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049151", 
            "org_study_id": "EMR 63325-021", 
            "secondary_id": "2013-003760-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tecemotide", 
                "description": "Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.", 
                "intervention_name": "Tecemotide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tecemotide", 
                "description": "CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.", 
                "intervention_name": "Cyclophosphamide (CPA)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.", 
                "intervention_name": "Saline (sodium chloride)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carcinoma, Non-Small-Cell Lung", 
            "Tecemotide", 
            "Placebo", 
            "NSCLC", 
            "L-BLP25"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "for US Recruiting Sites", 
                    "phone": "888-275-7376"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockland", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Please Contact U.S. Medical Information Located in"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "last_name": "for non-US Recruiting Sites", 
                    "phone": "+49 6151 72 5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please Contact the Merck KGaA Communication Center Located in"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_contact_backup": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Austria: Federal Office for Safety in Health Care", 
                "Australia: Human Research Ethics Committee", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: National Board of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Ireland: Irish Medicines Board", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "OS is defined as the time from randomization to death due to any cause.", 
            "measure": "Overall Survival (OS) Time", 
            "safety_issue": "No", 
            "time_frame": "From 1st randomization to about 54 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049151"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "TTSP is defined as the time from randomization to first documentation of symptom progression as measured by the Lung Cancer Symptom Scale.", 
                "measure": "Time to Symptom Progression (TTSP)", 
                "safety_issue": "No", 
                "time_frame": "From 1st randomization to about 54 months"
            }, 
            {
                "description": "PFS is defined as the time from randomization to the first documentation of progressive disease (PD) or to death due to any cause, whichever occurs first. PD is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 - Investigator read.", 
                "measure": "Progression-free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From 1st randomization to about 54 months"
            }, 
            {
                "description": "TTP is defined as the time from randomization to the first documentation of PD. PD is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 - Investigator read.", 
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "From 1st randomization to about 54 months"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}